Key result
Pharmacological treatments for aortic aneurysm fail to halt disease progression despite preclinical successes.
Why the study?
A paradox persists between preclinical successes and clinical failures, leaving no medical therapy currently available to ideally negate aortic aneurysm progression.
Do pharmacological treatments prevent the progression of aortic aneurysm?
Do pharmacological treatments prevent the progression of aortic aneurysm?
Despite preclinical successes, there is currently no effective pharmacological therapy proven to halt the progression of aortic aneurysms in clinical practice.
No medical therapy slows aortic aneurysm progression; leaves open the need for trials bridging preclinical promise to clinical efficacy.
Aortic aneurysm (AA) remains one of the primary causes of death worldwide. Of the major treatments, prophylactic operative repair is used for AA to avoid potential aortic dissection or rupture. To halt the development of AA and alleviate its progression into aortic dissection, pharmacological treatment has been investigated for years. Currently, β-adrenergic blocking agents, losartan, irbesartan, angiotensin-converting-enzyme inhibitors, statins, antiplatelet agents, doxycycline, and metformin have been investigated as potential candidates for preventing AA progression. However, the paradox between preclinical successes and clinical failures still exists, with no medical therapy currently available for ideally negating the disease progression. This review describes the current drugs used for pharmacological management of AA and their individual potential mechanisms. Preclinical models for drug screening and evaluation are also discussed to gain a better understanding of the underlying pathophysiology and ultimately find new therapeutic targets for AA.
No takes yet. Share an insight, caveat, or question.
Xiang et al. (2021) conducted a review in Aortic aneurysm. Pharmacological management was evaluated. Pharmacological treatments for aortic aneurysm currently show a paradox between preclinical successes and clinical failures, with no medical therapy available to ideally negate disease progression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: